Biotech deal­mak­er Ra­maswamy rais­es an­oth­er $55M for Ax­o­vant

One of biotech’s most promi­nent wheel­ers and deal­ers just nabbed an ex­tra $55 mil­lion to push along the pipeline at the neu­ro­sciences play­er Ax­o­vant.

Vivek Ra­maswamy, who’s been whip­ping up new com­pa­nies and rais­ing hun­dreds of mil­lions of dol­lars in IPOs, inked a debt fi­nanc­ing deal with Her­cules Cap­i­tal. Ra­maswamy will start off pay­ing in­ter­est for 18 months, then is in line to be­gin pay­ing back prin­ci­pal as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER